Pancreatic Cancer Research

ResearcherSalk Institute for Biological StudiesActive in the last 2 years

Tony R. Hunter

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-7691-6993; OpenAlex author ID A5001260440, A5010612497; NIH RePORTER profile ID 1866203. Sources: OpenAlex.

Their work

Papers
7 (first author 0, last author 2)
Trials
0
Grants
3
Labs led
1
Collaborators
48
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: none · 2017: none · 2018: none · 2019: 1 paper, 1 grant · 2020: none · 2021: 2 papers · 2022: none · 2023: 1 paper · 2024: none · 2025: 1 paper, 1 grant · 2026: 1 paper, 1 grant

Papers 7

  1. CA19-9 induces microenvironment remodeling in pancreatic ductal adenocarcinoma Co-author DOI 10.64898/2026.05.22.727290↗
  2. Clinical functional proteomics of intercellular signalling in pancreatic cancer. Co-author DOI 10.1038/s41586-024-08225-y↗
  3. Inhibiting stromal Class I HDACs curbs pancreatic cancer progression. Co-author DOI 10.1038/s41467-023-42178-6↗
  4. Author Correction: Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring. Last author DOI 10.1038/s41586-021-04176-w↗
  5. An engineered ligand trap inhibits leukemia inhibitory factor as pancreatic cancer treatment strategy. Co-author DOI 10.1038/s42003-021-01928-2↗
  6. Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring. Last author DOI 10.1038/s41586-019-1130-6↗
  7. Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy. Co-author DOI 10.1016/j.cell.2014.08.007↗

Grants 3

  1. Core 3: Mouse Models Core (MM Core) P01CA265762↗
  2. Histidine phosphorylation as a new target for cancer therapy R35CA242443↗
  3. Signal Transduction by Tyrosine Phosphorylation R01CA082683↗

Closest collaborators

The 25 strongest of 48 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ronald M. Evans · 5 shared papers, 1 shared grant, 2014–2026 · strength 1.22
  2. Dannielle D. Engle · 3 shared papers, 1 shared grant, 2014–2026 · strength 1.07
  3. Hervé Tiriac · 3 shared papers, 1 shared grant, 2014–2026 · strength 1.07
  4. Geoffrey Myles Wahl · 3 shared papers, 1 shared grant, 2014–2026 · strength 0.89
  5. Reuben Shaw · 1 shared grant, 2026 · strength 0.71
  6. Yu Shi · 5 shared papers, 2019–2025 · strength 0.60
  7. Peiwu Huang · 3 shared papers, 2019–2025 · strength 0.34
  8. Ruijun Tian · 3 shared papers, 2019–2025 · strength 0.34
  9. Andrew M. Lowy · 3 shared papers, 2019–2026 · strength 0.34
  10. Gaoyang Liang · 3 shared papers, 2019–2023 · strength 0.28
  11. Corina E. Antal · 3 shared papers, 2019–2023 · strength 0.28
  12. Daniel D. Von Hoff · 3 shared papers, 2019–2023 · strength 0.28
  13. Yehan Zhang · 1 shared paper, 2025 · strength 0.20
  14. Yunguang Li · 1 shared paper, 2025 · strength 0.20
  15. Min Wang · 1 shared paper, 2025 · strength 0.20
  16. Dong Gao · 1 shared paper, 2025 · strength 0.20
  17. Renyi Qin · 1 shared paper, 2025 · strength 0.20
  18. Jasper Hsu · 1 shared paper, 2026 · strength 0.20
  19. Jan C. Lumibao · 1 shared paper, 2026 · strength 0.20
  20. Casie S. Kubota · 1 shared paper, 2026 · strength 0.20
  21. Satoshi Ogawa · 1 shared paper, 2026 · strength 0.20
  22. Susan M Kaech · 1 shared paper, 2026 · strength 0.20
  23. Hyemin Song · 1 shared paper, 2026 · strength 0.20
  24. Timothy R. Donahue · 3 shared papers, 2014–2021 · strength 0.17
  25. Eric Andrew Collisson · 3 shared papers, 2014–2021 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.